BioXcel Therapeutics Bolsters Cash Reserves To Advance SERENITY At-Home Phase 3 Trial, Topline Data Expected In H2 2025

Benzinga · 03/11 12:13

Topline data expected in second half of 2025 to support potential sNDA submission for label expansion of IGALMI® in the home setting

Company has $35M of cash following closing of recent equity financing